Condition Guide
Peptides for Fatty Liver Disease (MASH / NAFLD)
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is an emerging target for incretin-based peptide therapy. Semaglutide, tirzepatide, and retatrutide all demonstrate meaningful reductions in hepatic fat.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
How peptides help
Incretin agonists reduce liver fat through weight loss, improved insulin sensitivity, and direct hepatic effects. Triple agonists with glucagon receptor activity may be particularly effective due to glucagon-mediated lipid oxidation.
Peptides researched for fatty liver disease (mash / nafld)
Semaglutide
Moderate EvidenceL5Phase II data shows MASH resolution.
630 studies · GLP-1 Receptor Agonism
Tirzepatide
Moderate EvidenceL5SYNERGY-NASH showed significant MASH resolution.
180 studies · Dual GIP/GLP-1 Agonism
Retatrutide
Moderate EvidenceL4Phase II ~80% MASH resolution; best-in-class liver fat reduction.
31 studies · Triple GIP/GLP-1/Glucagon Agonism
State of the evidence
Semaglutide has Phase II MASH data showing resolution of steatohepatitis. Retatrutide Phase II showed ~80% MASH resolution. Phase III trials ongoing.
Frequently asked
Can GLP-1 agonists reverse fatty liver?
Yes — trial data shows significant reductions in hepatic fat content and inflammation with GLP-1, dual, and triple agonists. Some patients achieve complete resolution of steatohepatitis.
Related articles & guides
What Are Peptides? A Science-Based Introduction
Guide · 12 min
Peptides for Weight Loss: What the Research Shows
Guide · 15 min
FDA Regulation of Peptides: What You Need to Know
Guide · 10 min
Peptides for Women: Safety, Benefits, and What’s Different
Deep Dive · 14 min
Ozempic Side Effects: What 5 Years of Real-World Data Actually Shows
Safety · 15 min
Oral Wegovy Pill Gets FDA Approval: What You Need to Know
Regulatory · 7 min
Retatrutide Phase 3: Triple Agonist Delivers 71 lbs Average Weight Loss
Clinical Trials · 6 min
Semaglutide Could Cost $3/Month: Patent Expiry and Generic Timeline
Industry · 6 min
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Show
Research · 9 min
Related conditions
Type 2 Diabetes
Incretin-based peptides improve glycemic control, reduce HbA1c, and provide cardiovascular benefits.
Weight Loss
Peptides that reduce appetite, slow gastric emptying, and improve metabolic health for sustained weight loss.
Metabolic Syndrome
Incretin and mitochondrial peptides improve insulin sensitivity, blood pressure, and lipid profile.